Cardiff Oncology, Inc. CRDF
Cardiff Oncology, Inc. (Nasdaq: CRDF) is an oncology drug developer. Its lead program, Onvansertib (PLK1 inhibitor), CRDF-004, is in Phase 2 for First-line RAS-mutated metastatic colorectal cancer.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Onvansertib + FOLFIRI/bev (CRDF-004) | First-line RAS-mutated mCRC | small molecule | Phase 2 |
| Onvansertib monotherapy (investigator-initiated) | Relapsed SCLC | small molecule | Phase 2 |
| Onvansertib + NALIRIFOX (investigator-initiated) | First-line metastatic pancreatic cancer | small molecule | Phase 1 |
| Onvansertib + paclitaxel (investigator-initiated) | Metastatic triple-negative breast cancer | small molecule | Phase 1 |
| Onvansertib monotherapy (investigator-initiated) | CMML / MDS-MPN | small molecule | Phase 1 |
Recent results and decisions
- Jun 3, 2026positive Interim data (Mar 18, 2026 cutoff): onvansertib 30 mg + FOLFIRI/bev confirmed ORR 72.2% (13/18) vs 42.1% (8/19) for FOLFIRI/bev; median PFS not reached vs 12.2 months (investigator), HR 0.57; no unexpected toxicities.
72% ORR in randomized Phase 2 trial, +30% over SoC; median PFS not reached vs 12.2 months in SoC
Filing - Jun 3, 2026n/a Cardiff reports a successful FDA End-of-Phase 2 meeting, aligned on the registrational trial of 30 mg onvansertib + FOLFIRI/bev.
Successful End-of-Phase 2 meeting: aligned on the registrational trial in first-line RAS-mutated mCRC
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.